Charles Cai, MD, PhD
VP-Clinical Science Oncology, Deputy Head of Development,
Charles is responsible for providing strategic, scientific leadership to successfully execute and accelerate globalization of our Innovative Oncology pipeline. Prior to joining HengRui, Dr. Cai was Senior Global Clinical Development Leader at Bayer (2015-2021) following 15-years of academic and industrial tenure with increasing roles and responsibilities at MD Anderson Cancer Center, Intrexon, Novartis and Daiichi-Sankyo.
With the combination of rigorous scientific understanding and expertise with rational and insightful perspectives on clinical and commercial strategy, Dr. Cai successfully led IND filings and phase 1-3 global clinical studies with different sub-therapeutic areas in oncology. His experience spans clinical development of immunotherapy, antibodies, mAb-ADCs and small molecule compounds such as copanlisib and capmatinib (INC280). His achievements in science and drug development have been well recognized by academic and industrial awards such as Cozzarelli Prize from the Proceedings of National Academy of Sciences, awards from American Association for Cancer Research, and Top Performance Award from Bayer.